



Boston
Scientific
Advancing science for life™

Science.
Humanity.
Purpose.

About This Addendum

The 2020 Performance Report Addendum supports the information available in our 2020 Performance Report, and was prepared by referencing the Global Reporting Initiative (GRI) guidelines.

Unless otherwise indicated, data in the 2020 Performance Report Addendum are as of December 31, 2020, or for the one-year period ending in December 31, 2020, as applicable.



Engaging With Our Stakeholders

Our corporate social responsibility (CSR) strategy, material topics and practices are informed by conversations with diverse stakeholders inside and outside the company — locally, nationally and globally.

In our collaborations and other business relationships, we work with organizations that share our commitment to better understand and improve environmental, social and economic progress.

The following chart outlines our material topics — CSR issues of greatest importance to Boston Scientific and our stakeholders — and how we are engaging to advance progress. Our CSR approach is informed by the United Nations Sustainable Development Goals (SDGs).

**SUSTAINABLE
DEVELOPMENT GOALS (SDGs)
AND MATERIAL TOPICS****SDGs****TRANSFORMING
CARE****INVESTING IN
OUR PEOPLE****ADVANCING
POSSIBILITIES****PROTECTING THE
ENVIRONMENT****CREATING VALUE
RESPONSIBLY****Material Topics**

- Innovative products

- Career, culture and talent
- Diversity, equity and inclusion (DE&I)
- Worker health and safety

- Community engagement

- Environmental impact
- Climate change

- Governance
- Compliance and ethics
- Sustainable supply chain

**STAKEHOLDER
ENGAGEMENT****Health Care Professionals
and Administrators**

- Value-based health care
- Training and medical education
- Clinical research and trials
- Customer care
- Digital health advancements
- Collaborative product development

- Global multidisciplinary training and education programs

- Medical research, educational programs and charitable giving
- Clinical trial equity
- Signature Health Grant training

- Environmentally preferred purchasing
- Custom waste solutions
- Consolidated shipping

- Business continuity and resiliency planning
- Clinical trial management
- Risk management structure
- Post-market surveillance
- Regulatory compliance
- Product usability improvements

**Patients and Patient
Advocacy Groups**

- Clinical trials
- Access to care
- Post-market feedback
- Advocacy group engagement

- Sharing patient stories at annual events and ongoing communications

- Health equity and access to care
- Product donations
- Chronic disease programs

- Carbon footprint and climate risk reduction

- Data privacy protection
- Customer service and complaint handling

STAKEHOLDER ENGAGEMENT	TRANSFORMING CARE	INVESTING IN OUR PEOPLE	ADVANCING POSSIBILITIES	PROTECTING THE ENVIRONMENT	CREATING VALUE RESPONSIBLY
Employees	<ul style="list-style-type: none"> ■ Innovation and recognition programs ■ Global quality system training ■ Global networking and collaboration programs 	<ul style="list-style-type: none"> ■ Career coaching and development ■ Employee surveys ■ Inclusion initiatives ■ Employee resource groups ■ Safety and wellness programs ■ Pay equity and inclusive benefits ■ Awards and recognition 	<ul style="list-style-type: none"> ■ Volunteering ■ Matching gift program ■ Donation programs ■ Global engagement campaigns 	<ul style="list-style-type: none"> ■ Green teams ■ Waste management and global recycling reporting ■ Energy and environmental management systems certification 	<ul style="list-style-type: none"> ■ Employee training: <ul style="list-style-type: none"> – Annual code of conduct and business ethics – Privacy and cyber security – Workplace safety – Unconscious bias
Shareholders and Institutional Investors	<ul style="list-style-type: none"> ■ Engagement on product innovations, acquisitions and global growth initiatives ■ Investor day 	<ul style="list-style-type: none"> ■ Engagement and reporting on labor practices, human rights and DE&I ■ Bloomberg Gender Equality Index member 	<ul style="list-style-type: none"> ■ Engagement on access to care and health equity 	<ul style="list-style-type: none"> ■ 2030 Carbon Neutrality Pledge 	<ul style="list-style-type: none"> ■ Engagement on governance issues ■ JUST Capital: JUST 100 Index ■ Dow Jones Sustainability North America Index member
Government Regulators and Policymakers	<ul style="list-style-type: none"> ■ Public-private partnerships that increase access to care ■ Medical Device Innovation Consortium and alliances membership 	<ul style="list-style-type: none"> ■ U.S. Equal Employment Opportunity reporting ■ European works councils ■ Gender pay gap reporting ■ Labor and human rights laws and policies 	<ul style="list-style-type: none"> ■ Advocacy for access to health care 	<ul style="list-style-type: none"> ■ Compliance assurance programs ■ Energy and environmental management systems certification 	<ul style="list-style-type: none"> ■ Legal and regulatory compliance ■ Public policy engagement
Nongovernmental Organizations and Local Communities	<ul style="list-style-type: none"> ■ Collaborations with academic institutions, research organizations and health care accelerators and startups 	<ul style="list-style-type: none"> ■ Learning institution collaborations ■ Underrepresented group sponsorships and partnerships 	<ul style="list-style-type: none"> ■ Boston Scientific Foundation ■ Charitable giving ■ Employee volunteering ■ Relief Campaigns ■ Global Signature Health Grants ■ Scholarships and internships 	<ul style="list-style-type: none"> ■ Renewable Energy Buyers Alliance 	<ul style="list-style-type: none"> ■ Quality standards and patient access advocacy
Suppliers and Distributors	<ul style="list-style-type: none"> ■ Global Supplier Guidebook: Quality ■ Business reviews on quality requirements and standards 	<ul style="list-style-type: none"> ■ Global Supplier Guidebook: safe and healthy workplace and human rights 	<ul style="list-style-type: none"> ■ Global Supplier Guidebook: supplier diversity guidelines ■ Diverse supplier collaborations 	<ul style="list-style-type: none"> ■ Global Supplier Guidebook: environmental responsibility requirements ■ Environmental management system engagement 	<ul style="list-style-type: none"> ■ Global Supplier Guidebook: human rights, business integrity, and supplier quality system assessments

Global Reporting Initiative (GRI) Index

The GRI Index includes references to our 2020 Performance Report, Annual Proxy Statement, financial reports, and Corporate Governance Guidelines available on [BostonScientific.com](https://www.bostonscientific.com).

We invest significantly in assessing and reporting our environmental, social and economic impacts to ensure we are making measurable contributions to the world we share. We continue to expand the scope of our CSR metrics and disclosures, and our priority is to report at the GRI Comprehensive level by 2024, if not sooner.

Page numbers in the index correspond to the 2020 Performance Report and the 2020 Form 10-K.

GRI 100

Indicator & Description		Response
102-1	Name of the organization	Boston Scientific Corporation
102-2	Activities, brands, products, and services	Form 10-K , Item 1. Business, Page 3 Performance Report , Meaningful Innovation, Page 8
102-3	Location of headquarters	300 Boston Scientific Way, Marlborough, MA 01752-1234
102-4	Location of operations	Form 10-K , Item 1. International Operations, Page 10 Form 10-K , Item 2. Properties, Page 37
102-5	Ownership and legal form	Boston Scientific Corporation, publicly traded on New York Stock Exchange as BSX
102-6	Markets served	Form 10-K , Item 1. Marketing and Sales, Page 10
102-7	Scale of the organization	Performance Report , Boston Scientific at a Glance, Page 7 Form 10-K , Item 1. Business, Page 3
102-8	Information on employees and other workers	Form 10-K , Item 1. Human Capital, Page 15 Performance Report Addendum
102-9	Supply chain	Form 10-K , Item 1. Manufacturing and Raw Materials, Page 10 Performance Report , Sustainable Supply Chain, Page 62
102-10	Significant changes to the organization and its supply chain	Form 10-K , Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations, Page 41
102-11	Precautionary Principle or approach	Form 10-K , Item 1. Corporate Social Responsibility, Page 16 Performance Report , Performance Report, CEO Letter — Adopting Environmentally Sustainable Business Practices, Page 6
102-12	External initiatives	Performance Report : United Nations Sustainable Development Goals, Page 10 CEO Action for Racial Equity Fellowship, Page 28 Global Human Rights and Labor Standards, Page 57
102-13	Membership of associations	Trade Association Memberships
102-14	Statement from senior decision-maker	Performance Report , A Message from Our Chairman, President and CEO, Page 4
102-15	Key impacts, risks, and opportunities	Form 10-K , Item 1A. Risk Factors, Page 20
102-16	Values, principles, standards, and norms of behavior	Boston Scientific Mission and Code of Conduct
102-17	Mechanisms for advice and concerns about ethics	Advice Line
102-18	Governance structure	Proxy Statement

GRI 100 (continued)

Indicator & Description		Response
102-19	Delegating authority	Proxy Statement
102-20	Executive-level responsibility for economic, environmental, and social topics	Performance Report , Corporate Social Responsibility at Boston Scientific, Page 10
102-21	Consulting stakeholders on economic, environmental, and social topics	Performance Report Addendum , Engaging with Stakeholders, page 3
102-22	Composition of the highest governance body and its committees	Proxy Statement
102-23	Chair of the highest governance body	Proxy Statement
102-24	Nominating and selecting the highest governance body	Proxy Statement
102-25	Conflicts of interest	Proxy Statement
102-26	Role of highest governance body in setting purpose, values, and strategy	Proxy Statement
102-27	Collective knowledge of highest governance body	Proxy Statement
102-28	Evaluating the highest governance body's performance	Proxy Statement
102-29	Identifying and managing economic, environmental, and social impacts	See 102-21
102-30	Effectiveness of risk management processes	Proxy Statement
102-31	Review of economic, environmental, and social topics	See 102-21
102-32	Highest governance body's role in sustainability reporting	Proxy Statement
102-33	Communicating critical concerns	Proxy Statement
102-34	Nature and total number of critical concerns	Form 10-K Item 1A. Risk Factors, Page 23
102-35	Remuneration policies	Proxy Statement
102-36	Process for determining remuneration	Proxy Statement
102-37	Stakeholders' involvement in remuneration	Proxy Statement

GRI 100 (continued)

Indicator & Description	Response
102-38 Annual total compensation ratio	Proxy Statement
102-39 Percentage increase in annual total compensation ratio	Proxy Statement
102-40 List of stakeholder groups	See 102-21
102-41 Collective bargaining agreements	Human Rights, Collective Bargaining
102-42 Identifying and selecting stakeholders	See 102-21
102-43 Approach to stakeholder engagement	See 102-21
102-44 Key topics and concerns raised	Performance Report , Corporate Social Responsibility at Boston Scientific, Page 10
102-45 Entities included in the consolidated financial statements	Form 10-K , Exhibit 21
102-46 Defining report content and topic Boundaries	Performance Report , Table of Contents, Page 3
102-47 List of material topics	See 102-21
102-48 Restatements of information	Throughout Performance Report and Addendum
102-49 Changes in reporting	Throughout Performance Report and Addendum
102-50 Reporting period	Data in the Performance Report covers the period between January 1, 2020, and December 31, 2020, unless otherwise indicated
102-51 Date of most recent report	Performance Report , A Message from Our Chairman, President and CEO, Page 6
102-52 Reporting cycle	Annual
102-53 Contact point for questions regarding the report	Investor Relations
102-54 Claims of reporting in accordance with the GRI Standards	Performance Report Addendum , Page 2
102-55 GRI content index	Performance Report Addendum
102-56 External assurance	This report has not been independently verified.

GRI 200

Indicator & Description		Response
201-1	Direct economic value generated and distributed	Performance Report , Boston Scientific at a Glance, Page 7 Form 10-K , Item 8 Financial Statements & Supplementary Data, Page 71
201-2	Financial implications and other risks and opportunities due to climate change	Form 10-K , Business and Manufacturing Risks, Page 26
201-3	Defined benefit plan obligations and other retirement plans	Form 10-K , Item 15. Exhibits and Financial Statement Schedules Note S, Page 132
202-1	Ratios of standard entry level wage by gender compared to local minimum wage	Labor and Human Rights, Commitment to Labor Initiatives or Standards
203-1	Infrastructure investments and services supported	Form 10-K , Marketing and Sales and International Operations, Page 10
203-2	Significant indirect economic impacts	Performance Report : Value-Based Health Care, Page 22 Learning from our Employee Resource Groups, Page 30 Confronting Health Inequities, Page 36 Playing Our Part: Combating Racism, Page 38 Supporting Our Communities, Page 39 Responding to Climate Change, Page 47 Our Environmental Impact, Page 50
204-1	Proportion of spending on local suppliers	Performance Report , Sustainable Supply Chain, Page 62
205-1	Operations assessed for risks related to corruption	Anti-Corruption & Governance Performance Report , Sustainable Supply Chain, Page 62
205-2	Communication and training about anti-corruption policies and procedures	Performance Report , Compliance, Ethics and Integrity, Page 56
206-1	Legal actions for anti-competitive behavior, anti-trust, and monopoly practices	Form 10-K , Note K. Commitments and Contingencies, Page 115

GRI 300

Indicator & Description		Response
302-1	Energy consumption within the organization	Performance Report , GEMS KPIs, Page 49
302-3	Energy intensity	Performance Report , GEMS KPIs, Page 49. Boston Scientific is a low energy intensity industry
302-4	Reduction of energy consumption	Performance Report , GEMS KPIs, Page 49
302-5	Reductions in energy requirements of products and services	Performance Report , GEMS KPIs, Page 49
303-1	Water withdrawal	Performance Report Addendum
303-2	Water discharge	Performance Report Addendum
303-3	Water consumption	Performance Report Addendum
305-1	Direct (Scope 1) GHG emissions	Performance Report Addendum
305-2	Energy indirect (Scope 2) GHG emissions	Performance Report Addendum
305-5	Reduction of GHG emissions	Performance Report , GEMS KPIs, Page 49
306-1	Water discharge by quality and destination	Performance Report Addendum
306-2	Waste by type and disposal method	Performance Report Addendum
306-3	Significant spills	No significant spills for 2020
306-4	Transport of hazardous waste	Performance Report Addendum
307-1	Non-compliance with environmental laws and regulations	Performance Report Addendum
308-1	New suppliers that were screened using environmental criteria	Performance Report Addendum

GRI 400

Indicator & Description		Response
401-1	New employee hires and employee turnover	Performance Report Addendum
401-2	Benefits provided to full-time employees that are not provided to temporary or part-time employees	Benefits
401-3	Parental leave	Benefits
403-2	Types of injury and rates of injury, occupational diseases, lost days, and absenteeism, and number of work-related fatalities	Performance Report Addendum
404-1	Average hours of training per year per employee	Performance Report , Employee Growth and Development, Page 26
404-2	Programs for upgrading employee skills and transition assistance programs	Performance Report , Employee Growth and Development, Page 26
404-3	Percentage of employees receiving regular performance and career development reviews	Performance Report , Global Strategic Talent Management and Planning, Page 25
405-1	Diversity of governance bodies and employees	Proxy Statement Performance Report Addendum
405-2	Ratio of basic salary and remuneration of women to men	Performance Report , Equal Pay for Equal Work, Page 32 Equal Pay for Equal Work
406-1	Incidents of discrimination and corrective actions taken	Compliance and Ethics
407-1	Operations and suppliers in which the right to freedom of association and collective bargaining may be at risk	Human Rights
408-1	Operations and suppliers at significant risk for incidents of child labor	Human Rights
409-1	Operations and suppliers at significant risk for incidents of forced or compulsory labor	Human Rights
411-1	Incidents of violations involving rights of indigenous peoples	Human Rights
412-1	Operations that have been subject to human rights reviews or impact assessments	Human Rights

GRI 400 (continued)

Indicator & Description		Response
412-2	Employee training on human rights policies or procedures	Human Rights
413-1	Operations with local community engagement, impact assessments, and development programs	Performance Report , Supporting Our Communities, Page 39 Community Engagement
414-1	New suppliers that were screened using social criteria	Performance Report , Sustainable Supply Chain, Page 62
415-1	Political contributions	Political Contributions
416-1	Assessment of the health and safety impacts of product and service categories	Performance Report , Our Approach to Innovative and Quality Products, Page 12
416-2	Incidents of non-compliance concerning the health and safety impacts of products and services	Performance Report , Measuring and Monitoring Quality and Compliance Effectiveness, Page 15 Performance Report Addendum
417-1	Requirements for product and service information and labeling	Performance Report , Packaging and Labeling, Page 63
419-1	Non-compliance with laws and regulations in the social and economic area	Boston Scientific adheres to all compliance requirements, see compliance references throughout the Performance Report

Metrics Summary

Our Metrics Summary provides the key performance data for each of our material topics, which align with ten of the seventeen United Nations Sustainable Development Goals (SDGs).

METRIC	UNIT	2018	2019	2020
Organizational Profile				
No. Employees	#	32,000	36,000	38,000
Revenues	USD Millions	9,823	10,735	9,913
Operating Expenses	USD Millions	5,504	6,102	6,528
Community Engagement				
Monetary value of Philanthropic Contributions Cash Contributions	USD Millions	8.90	8.14	9.04
Boston Scientific Foundation Cash Contributions	USD Millions	1.07	1.19	1.21
Employee Volunteering Hours	Hours	43,000	41,000	23,000
Overhead Costs for Management of Philanthropic Activities	USD Millions	0.068	0.067	0.200*
*2020 data includes community engagement, sales charitable contributions committee costs and foundation consultant fees.				
Career & Culture				
Employee Turnover Rate	Percent Total Employees	11.9	12.0	10.3
Voluntary Employee Turnover Rate	Percent Total Employees	9.5	9.5	7.1
Work Related Fatalities – Employees	#	0	0	0
Work Related Fatalities – Contractors	#	0	0	0
Total Recordable Incident Rate (TRIR)	Injuries per 100 Employees	0.52	0.53	0.47
Total Recordable Injury Frequency Rate (TRIFR)	Injuries per 1 Million Hours Worked	2.6	2.7	2.3
Lost Time Injury Frequency Rate (LTIFR)	Lost Time Injuries per 1 Million Hours Worked	—	—	1.7*
Occupational Lost Time Rate (OLTR)	Lost Time Days per 100 Employees	—	5.9	4.7
TRIR, TRIFR, LTIFR AND OLTR Rate Coverage	Percent of Employees	66	66	67
Open positions filled by internal candidates	Percent	20.1	47.0	20.5
Period that long-term incentives for employees are paid out after	Years	4	4	4**

*Boston Scientific has always reported using TRIR and will expand reporting to include LTIFR from 2020.

**4 yrs (25% per year) is the vesting for options and restricted units. Half of the value delivered to Executives is through performance share units which have a 3-year cliff vest.

METRIC	UNIT	2018	2019	2020
Diversity & Inclusion				
Share of Total Workforce – Women	Percent	46.5	47.0	47.4
Supervisors and Managers – Women*	Percent	38.4	38.1	39.9
Senior Management – Women**	Percent	29.5	31	33.2
Executive Officers – Women***	Percent	17.6****	18.8	25.0
Board of Directors – Women	Percent	30.0	30.0	30.0
Share of Total Field Sales Management Positions – Women	Percent	22.0	21.3	22.9
Supervisors and Managers – Multicultural Talent*****	Percent	19.6	20.8	21.4

*Supervisors and Managers includes all levels that are supervisor, manager I and manager II.

**Senior Management includes all levels that are director, vice president, senior vice president, executive vice president and CEO.

***Executive Officers includes all executive committee members listed in the company's Annual Report.

****Data for 2018 has been updated to reflect correct executive committee designation historically.

***** Multicultural: In the U.S. and Puerto Rico, defined as African American/Black, Hispanic/Latino, American Indian/Alaska Native, Native Hawaiian/Other Pacific Islander, and two or more races. Excludes any U.S. Puerto Rico employees where the ethnicity is "Unallocated."

For more information, visit our DE&I website: <https://www.bostonscientific.com/en-US/careers/working-here/diversity-and-inclusion.html>

Climate Change

Total Direct Greenhouse Gas (GHG) Emissions Scope 1	CO2 Equivalent Metric Tons	31,257	34,168	35,908
Total Indirect GHG Emissions Scope 2	CO2 Equivalent Metric Tons	53,870	50,611	17,823
Non-renewable Fuels Consumed	mWh	170,495	186,393	191,645
Total Electricity Purchased	mWh	181,587	187,736	185,329
Non-renewable Electricity Purchased	mWh	147,384	130,860	28,914
Total Renewable Electricity Purchased	mWh	9,149	22,508	156,415
Total Energy Use	gWh	355	368	381
Green Real Estate*	Percent	32	41	42
Carbon Footprint	Metric Tons	85,127	84,778	53,730
Renewable Electricity with Renewable Energy Certificates (RECs)	Percent	5	11	71
Renewable Energy all Sources with RECs	Percent	3	6	35

*2018 and 2019 numbers restated.

METRIC	UNIT	2018	2019	2020
Environmental Impact*				
Total Municipal Water Consumed	Million Cubic Meters	0.568	0.581	0.618
Total Fresh Water Consumed	Million Cubic Meters	0.121	0.109	0.119
Total Process Water Discharged	Million Cubic Meters	0.057	0.068**	0.109
Total Domestic Water Discharged	Million Cubic Meters	0.412	0.430	0.511
Total Non-hazardous and Hazardous Waste Generated	Metric Tons	12,372	12,196	10,936
Total Non-hazardous Waste Generated	Metric Tons	11,579	11,200	9,978
Total Non-hazardous Waste Recycled	Metric Tons	9,667	8,943	7,843
Total Non-hazardous Waste Energy Recovered	Metric Tons	1,332	1,744	1,545
Total Non-hazardous Waste Disposed to Landfill	Metric Tons	581	514	591
Total Hazardous Waste Generated	Metric Tons	792	996	958
Total Hazardous Waste Recovered	Metric Tons	76	57	94
Total Hazardous Waste Energy Recovered	Metric Tons	310	362	376
Total Hazardous Waste Treatment	Metric Tons	247	240	292
Total Hazardous Waste Incinerated	Metric Tons	135	218	152
Total Hazardous Waste Landfilled	Metric Tons	0	0	14
Total Hazardous Waste Recycled	Metric Tons	24	119	29
Environmental Notice of Violation	#	0	3	0

*Environmental and Climate Change metrics coverage represents greater than 75% of our key business operations.

**2019 figure corrected.

METRIC	UNIT	2018	2019	2020
Sustainable Supply Chain				
Identification of Critical Suppliers – total Tier 1 Suppliers	#	1,498	1,650	1,498
Identification of Critical Suppliers – total Tier 1 Suppliers	Percent	100	100	100
Identification of Critical Suppliers – Total Tier 1 Critical Suppliers	#	153	141	137
Identification of Critical Suppliers – Total Tier 1 Critical Suppliers	Percent	10.21	8.55	9.20
Supplier Scorecard Risk Assessment Tier 1 Suppliers Assessed in last 3 years	#	393	333	337
Supplier Scorecard Risk Assessment Tier 1 Suppliers Assessed in last 3 years	Percent	26.30	20.18	22.63
Comprehensive assessment of Critical (Tier 1 and Non-Tier 1) Suppliers Annually	Percent	10.21	8.60	9.20
Comprehensive assessment of Critical (Tier 1 and Non-Tier 1) Suppliers in the Last 3 Years	Percent	26.23	20.20	22.60

METRIC	UNIT	2018	2019	2020
Compliance				
Anti Competitive Practices Fines	Yes/No	No	No	No
Corruption & Bribery Cases	#	0	0	0
Earnings before Tax	USD Millions	1,422	687	-79
Reported Taxes	USD Millions	-249	-4,013	2
Reported Tax Rate	Percent	-17.5	-584.0	2.9
Cash Taxes Paid	USD Millions	1,037	242	207
Upheld regulatory complaints concerning marketing and selling practices	#	0	0	0
Upheld self regulatory complaints concerning marketing and selling practices	#	0	0	0
Innovative Products				
Class I Recalls	#	0	0	3
Value of Class I Recalled Products	USD Millions	0	0	77.09
Class II Recalls	#	5	7	15
Value of Recalled Products*	USD Millions	1.22	9.60	59.01
Regulatory Inspections	#	76	87	85
Form 483 Observations	#	7	0	0
Annual Revenues from 483 affected facilities	USD Millions	107	0	0
Annual Revenues impacted by production stoppages	USD Millions	0	0	0
FDA Warning letters	Yes/No	No	No	No
Research & Development Spend	USD Millions	1,113	1,174	1,143
Research & Development Spend as Percent of Sales	%	11	11	12
No. of R&D Positions	FTE	1,453	2,040	2,114

*Of the recalls classified in the year, value is determined by recall quantity multiplied by cost to manufacture.

METRIC	UNIT	2018	2019	2020
Governance				
No. of Executive Directors	#	1	1	1
No. of Independent Directors	#	9	9	9
No. of Women Executives	#	3	3	4
Average Tenure of board members (Years)	#	5	6	7
No. of non-executive/independent directors with 4 or less Board Mandates	#	9	9	8
No. of other mandates for non-executive/independent directors restricted to:*	#	3**	3**	3
Performance Period Covered by Executive Compensation Plan	Years	3	3	3
Clawback Provision for Executive Compensation Plan	Yes/No	Yes	Yes	Yes
Reporting Rights per 1 Share (Based on Form 10-K)	No. of Votes	1,385,961,926	1,396,195,349	1,417,165,707
Total Annual CEO Compensation	USD Millions	13.97	15.76	13.77
Median Annual Compensation for all Employees	USD Thousands	62.45	65.63	59.30
Lobbying	USD Millions	1.68	1.68	1.52
Lobbying – Local, Regional or National Political Campaigns	USD Millions	0.27	0.26	0.25
Lobbying – Trade Associations	USD Millions	0.14	0.14	0.13

*Without the approval of the Nominating and Governance Committee, no director may sit on more than four public company boards (including the Company's board).
<https://investors.bostonscientific.com/-/media/Files/B/Boston-Scientific-IR-V3/documents/corporate-governance/bsx-corporate-governance-guidelines-feb-2020.pdf>

**2018 and 2019 numbers restated.



Boston Scientific Corporation
300 Boston Scientific Way
Marlborough, MA 01752-1234
bostonscientific.com